Sequential myeloablative autologous stem cell transplantation and reduced intensity allogeneic hematopoietic cell transplantation is safe and feasible in children, adolescents and young adults with poor-risk refractory or recurrent Hodgkin and non-Hodgkin lymphomaPrakash Satwani, Mitchell S. Cairo, Sonali Chaudhury et al.|Leukemia|2014Cited by 53
Abatacept for GVHD Prophylaxis after Hematopoietic Stem Cell Transplantation (HCT) for Pediatric Sickle Cell Disease (SCD): A Sickle Transplant Alliance for Research (STAR) TrialSonali Chaudhury, Monica Bhatia, Joe Laskowski et al.|Transplantation and Cellular Therapy|2018Cited by 13
Sequential Myeloablative Autologous Stem Cell Transplantation and Reduced Intensity Allogeneic Stem Cell Transplantation in Children, Adolescents and Young Adults with Poor Risk Refractory or Recurrent Hodgkin (HL) and Non-Hodgkin Lymphoma (NHL)Prakash Satwani, Mitchell S. Cairo, Joanne Kurtzberg et al.|Transplantation and Cellular Therapy|2014Cited by 1